Patent ID: 8865653

Claim:
A method of treating a subject having a tumor identified as resistant to a conventional immunogenic treatment of cancer, wherein the method comprises: a step of determining the ability of the tumor to induce an anticancer immune response, said step comprising verifying the expression by tumor cells of nuclear HMGB1, wherein the absence of nuclear HMGB1 in tumor cells is indicative of the inability of the tumor to induce an anticancer immune response and the inability of the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the conventional immunogenic treatment of cancer wherein the presence of nuclear HMGB1 in tumor cells is indicative of the ability of the tumor to induce an anticancer immune response and the ability of the tumor to induce an anticancer immune response being indicative of the subject's sensitivity to the conventional immunogenic treatment of cancer, and a step of treating a subject identified as resistant to said conventional immunogenic treatment of cancer with a composition comprising, dendrophilin in combination with a conventional immunogenic treatment of cancer selected from an anthracyclin, a platin, a taxane, a cyclophosphamide and an antimotic agent; and radiotherapy.